ArticleAdvanced functional materials2010
Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide.
Article in Advanced functional materials, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 81 citations in OpenAlex.
- Longer Acting Injectable: Continuous, Linear Release of a Progestin Contraceptive From an Oxidized Porous Silicon Host.Advanced healthcare materials · 2025Article
- Local controlled release of stabilized monoclonal antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Reinforced Polymer-Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of Trastuzumab.Advanced healthcare materials · 2025Article
- Intracellular delivery of proteins for live cell imaging.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Enteric Polymer-Coated Porous Silicon Nanoparticles for Site-Specific Oral Delivery of IgA Antibody.ACS biomaterials science & engineering · 2022Article
- Porous Silicon Nanoparticles Targeted to the Extracellular Matrix for Therapeutic Protein Delivery in Traumatic Brain Injury.Bioconjugate chemistry · 2022Article
- Antimicrobial peptides for bone tissue engineering: Diversity, effects and applications.Frontiers in bioengineering and biotechnology · 2022Review
- Relevance of Electrostatics for the Interaction of Tyrosine Hydroxylase with Porous Silicon Nanoparticles.Molecular pharmaceutics · 2021Article
- Nanomaterials for Protein Delivery in Anticancer Applications.Pharmaceutics · 2021Review
- Potential Applications of Nanomaterials and Technology for Diabetic Wound Healing.International journal of nanomedicine · 2020Review
- Bone Morphogenic Protein 2-Loaded Porous Silicon Carriers for Osteoinductive Implants.Pharmaceutics · 2019Article
- Freeze-dried matrices for ocular administration of bevacizumab: a comparison between subconjunctival and intravitreal administration in rabbits.Drug delivery and translational research · 2018Article
- Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus.Nature communications · 2018Article
- Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery.Journal of materials science. Materials in medicine · 2015Article
- Protection and Delivery of Anthelmintic Protein Cry5B to Nematodes Using Mesoporous Silicon Particles.ACS nano · 2015Article
- Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.Acta biomaterialia · 2014Article
- Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab.Molecular pharmaceutics · 2013Article
- Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2013Article
- Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis.Journal of pharmaceutical and biomedical analysis · 2011Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Nanostructured mesoporous silica (SiO(2)) films are used to load and release the monoclonal antibody bevacizumab (Avastin) in vitro. A biocompatible and biodegradable form of mesoporous SiO(2) is prepared by electrochemical etching of single crystalline Si, followed by thermal oxidation in air at 800 °C. Porous SiO(2) exhibits a negative surface charge at physiological pH (7.4), allowing it to spontaneously adsorb the positively charged antibody from an aqueous phosphate buffered saline solution. This electrostatic adsorption allows bevacizumab to be concentrated by >100× (300 mg bevacziumab per gram of porous SiO(2) when loaded from a 1 mg mL(-1) solution of bevacziumab). Drug loading is monitored by optical interferometric measurements of the thin porous film. A two-component Bruggeman effective medium model is employed to calculate percent porosity and film thickness, and is further used to determine the extent of drug loading into the porous SiO(2) film. In vitro drug release profiles are characterized by an enzyme-linked immunosorbent assay (ELISA), which confirms that the antibody is released in its active, VEGF-binding form. The nanostructured delivery system described here provides a sustained release of the monoclonal antibody where approximately 98% of drug is released over a period of one month.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.